Orexo

Orexo was established in Uppsala, Sweden, in 1995 with the goal of improving pharmaceutical goods to address unmet patient requirements. In 2000, the business registered Diabact® UBT, a breath test for detecting the stomach ulcer-causing bacterium Helicobacter pylori. From an R&D stage firm to a viable pharmaceutical company with commercial operations in the US, Orexo has evolved.

The business wants to lead the way in the treatment of opioid addiction. The American market for buprenorphine/naloxone medicines and the commercialization of Zubsolv®, a medication that is successful in treating opioid addiction, are Orexo's main markets. According to CEO Nikolaj Srensen, "Three of their four internal pipeline projects are ready to progress into the next development phase, their financial position continues to strengthen due to sales growth, and their manufacturing efficiency program has had a significantly positive impact on the gross profit contribution from Zubsolv." These factors all point to a bright future for the company in 2019. Orexo was enlisted on the Nasdaq Stockholm in 2005.

Founded: 1995

Number of employees: 123 employees

Headquarters: Uppsala, Sweden
Website: https://orexo.com/